179.58

2.21% 3.89

Charles River Laboratories International Inc (CRL)

Overview News Price History Option Chain Financials Discussions Forecast

Charles River Laboratories International Inc stock is traded at $179.58, with a volume of 742.83K. It is up +2.21% in the last 24 hours and down -10.93% over the past month. Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Previous Close:

$175.69

Open:

$176.06

24h Volume:

742.83K

Relative Volume:

0.85

Market Cap:

$8.84B

Revenue:

$4.02B

Net Income/Loss:

$-79.62M

P/E Ratio:

-115.48

EPS:

-1.5551

Net Cash Flow:

$543.67M

1W Performance:

+7.17%

1M Performance:

-10.93%

6M Performance:

+10.64%

1Y Performance:

+9.29%

1-Day Range:

$175.50

$181.01

1-Week Range:

$166.59

$181.01

52-Week Range:

$91.86

$228.88

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name

Charles River Laboratories International Inc

Sector

Healthcare (1106)

Industry

Diagnostics & Research (52)

Phone

781-222-6000

Address

251 BALLARDVALE ST, WILMINGTON, MA

Employee

19,700

Twitter

@criverlabs

Next Earnings Date

2024-11-06

Latest SEC Filings

CRL's Discussions on Twitter

Compare CRL vs TMO, DHR, IDXX, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRL Charles River Laboratories International Inc	179.58	8.65B	4.02B	-79.62M	543.67M	-1.5551
TMO Thermo Fisher Scientific Inc	512.69	190.90B	44.56B	6.73B	6.29B	17.74
DHR Danaher Corp	204.73	144.26B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	648.70	50.60B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	120.54	33.67B	6.95B	1.30B	1.15B	4.5696
WAT Waters Corp	319.04	30.62B	3.17B	642.63M	516.49M	10.77

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-15-25	Upgrade	BofA Securities	Neutral → Buy
Nov-17-25	Upgrade	Argus	Hold → Buy
Nov-06-25	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-06-25	Upgrade	William Blair	Mkt Perform → Outperform
Oct-02-25	Upgrade	Barclays	Equal Weight → Overweight
Sep-09-25	Upgrade	Jefferies	Hold → Buy
Jul-09-25	Upgrade	Citigroup	Neutral → Buy
May-23-25	Upgrade	Redburn Atlantic	Neutral → Buy
May-14-25	Upgrade	TD Cowen	Hold → Buy
May-08-25	Upgrade	Evercore ISI	In-line → Outperform
Mar-21-25	Downgrade	Goldman	Buy → Neutral
Mar-04-25	Upgrade	Citigroup	Sell → Neutral
Mar-03-25	Upgrade	Redburn Atlantic	Sell → Neutral
Jan-22-25	Downgrade	William Blair	Outperform → Mkt Perform
Jan-17-25	Downgrade	UBS	Buy → Neutral
Nov-18-24	Downgrade	CLSA	Hold → Underperform
Nov-07-24	Upgrade	CLSA	Underperform → Hold
Oct-23-24	Initiated	CLSA	Underperform
Oct-14-24	Initiated	Redburn Atlantic	Sell
Oct-07-24	Downgrade	Evercore ISI	Outperform → In-line
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral
Oct-01-24	Downgrade	Citigroup	Neutral → Sell
Aug-08-24	Downgrade	JP Morgan	Overweight → Neutral
Aug-08-24	Downgrade	Robert W. Baird	Outperform → Neutral
Jun-28-24	Downgrade	Argus	Buy → Hold
Jun-07-24	Initiated	Mizuho	Neutral
Jun-06-24	Initiated	Goldman	Buy
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Sep-13-23	Initiated	TD Cowen	Market Perform
Jul-10-23	Downgrade	Citigroup	Buy → Neutral
Feb-23-23	Upgrade	Guggenheim	Neutral → Buy
Jan-12-23	Downgrade	Jefferies	Buy → Hold
Sep-30-22	Upgrade	Jefferies	Hold → Buy
Aug-25-22	Initiated	Credit Suisse	Outperform
Aug-04-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-24-22	Initiated	Guggenheim	Neutral
Apr-25-22	Downgrade	Jefferies	Buy → Hold
Apr-07-22	Initiated	Stephens	Overweight
Feb-17-22	Reiterated	BofA Securities	Buy
Feb-17-22	Upgrade	Citigroup	Neutral → Buy
Feb-17-22	Reiterated	Deutsche Bank	Buy
Feb-17-22	Reiterated	Morgan Stanley	Overweight
Feb-17-22	Reiterated	UBS	Buy
Aug-05-21	Resumed	Credit Suisse	Neutral
Dec-16-20	Downgrade	Citigroup	Buy → Neutral
Sep-10-20	Upgrade	Jefferies	Hold → Buy
Jul-01-20	Upgrade	BofA Securities	Neutral → Buy
May-13-20	Upgrade	UBS	Neutral → Buy
Apr-21-20	Downgrade	Jefferies	Buy → Hold
Mar-27-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-02-20	Initiated	Deutsche Bank	Buy
Feb-18-20	Upgrade	Wolfe Research	Peer Perform → Outperform
Jan-10-20	Upgrade	Goldman	Neutral → Buy
Jan-08-20	Initiated	Wells Fargo	Overweight
Jan-07-20	Initiated	Citigroup	Buy
Oct-18-19	Downgrade	BofA/Merrill	Buy → Neutral
Jun-10-19	Initiated	SVB Leerink	Outperform
Apr-30-19	Resumed	Evercore ISI	Outperform
Dec-14-18	Initiated	Deutsche Bank	Buy
Oct-09-18	Initiated	UBS	Neutral
Aug-23-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jul-17-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jun-15-18	Upgrade	KeyBanc Capital Mkts	Sector Weight → Overweight
Feb-14-18	Upgrade	SunTrust	Hold → Buy

View All

Charles River Laboratories International Inc Stock (CRL) Latest News

Mar 04, 2026

Charles River Laboratories: Why Wall Street Suddenly Cares About This Quiet Biotech Powerhouse - AD HOC NEWS

Mar 04, 2026

Insider Buying: Joseph Laplume Acquires Shares in Charles River Laboratories International Inc (CRL) - GuruFocus

Mar 04, 2026

Charles River (NYSE: CRL) CEO receives 16,796-share stock-based award - Stock Titan

Mar 04, 2026

Charles River (NYSE: CRL) EVP adds 25 shares in open-market buy - Stock Titan

Mar 04, 2026

Charles River Laboratories: Is Wall Street Underpricing This Quiet Biotech Enabler? - AD HOC NEWS

Mar 04, 2026

Charles River (CRL) Trims 2026 Outlook After Divestitures and Leadership Changes Is The Strategy Working? - simplywall.st

Mar 04, 2026